105 related articles for article (PubMed ID: 30702142)
21. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
22. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
23. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
24. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
[TBL] [Abstract][Full Text] [Related]
25. Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.
Swanson M; Ibrahim S; Blat C; Oketch S; Olwanda E; Maloba M; Huchko MJ
BMC Womens Health; 2018 Jul; 18(1):116. PubMed ID: 29970063
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.
Vanni T; Legood R; Franco EL; Villa LL; Luz PM; Schwartsmann G
Int J Cancer; 2011 Aug; 129(3):671-9. PubMed ID: 20886598
[TBL] [Abstract][Full Text] [Related]
27. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program.
Alfaro KM; Gage JC; Rosenbaum AJ; Ditzian LR; Maza M; Scarinci IC; Miranda E; Villalta S; Felix JC; Castle PE; Cremer ML
BMC Public Health; 2015 Oct; 15():1058. PubMed ID: 26474762
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
30. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
31. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
[TBL] [Abstract][Full Text] [Related]
32. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
[TBL] [Abstract][Full Text] [Related]
33. VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.
Xie Y; Tan X; Shao H; Liu Q; Tou J; Zhang Y; Luo Q; Xiang Q
BMC Public Health; 2017 Jan; 17(1):118. PubMed ID: 28122530
[TBL] [Abstract][Full Text] [Related]
34. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial.
Broberg G; Gyrd-Hansen D; Miao Jonasson J; Ryd ML; Holtenman M; Milsom I; Strander B
Int J Cancer; 2014 May; 134(9):2223-30. PubMed ID: 24127304
[TBL] [Abstract][Full Text] [Related]
35. The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.
Burger EA; Sy S; Nygård M; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2017 Jan; 26(1):95-103. PubMed ID: 27624639
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
37. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
[TBL] [Abstract][Full Text] [Related]
38. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
39. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
Pedersen K; Burger EA; Sy S; Kristiansen IS; Kim JJ
Gynecol Oncol; 2016 Nov; 143(2):326-333. PubMed ID: 27542966
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
